Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB; Platinum Study Group. Kerns SL, et al. Among authors: kollmannsberger c. J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4. J Clin Oncol. 2018. PMID: 29617189 Free PMC article.
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C. Bokemeyer C, et al. Among authors: kollmannsberger c. J Clin Oncol. 1999 Nov;17(11):3450-6. doi: 10.1200/JCO.1999.17.11.3450. J Clin Oncol. 1999. PMID: 10550141
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C; German Testicular Cancer Study Group. Schmoll HJ, et al. Among authors: kollmannsberger c. J Clin Oncol. 2003 Nov 15;21(22):4083-91. doi: 10.1200/JCO.2003.09.035. Epub 2003 Oct 20. J Clin Oncol. 2003. PMID: 14568987 Clinical Trial.
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, Rick O, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C. Kollmannsberger C, et al. J Clin Oncol. 2004 Jan 1;22(1):108-14. doi: 10.1200/JCO.2004.06.068. J Clin Oncol. 2004. PMID: 14701772 Clinical Trial.
Treatment of germ cell tumors--update 2006.
Kollmannsberger C, Honecker F, Bokemeyer C. Kollmannsberger C, et al. Ann Oncol. 2006 Sep;17 Suppl 10:x31-5. doi: 10.1093/annonc/mdl232. Ann Oncol. 2006. PMID: 17018745 Free article. Review. No abstract available.
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study Group. Lorch A, et al. Among authors: kollmannsberger c. J Clin Oncol. 2007 Jul 1;25(19):2778-84. doi: 10.1200/JCO.2006.09.2148. J Clin Oncol. 2007. PMID: 17602082 Clinical Trial.
Pharmacotherapy of relapsed metastatic testicular cancer.
Kollmannsberger C, Honecker F, Bokemeyer C. Kollmannsberger C, et al. Expert Opin Pharmacother. 2008 Sep;9(13):2259-72. doi: 10.1517/14656566.9.13.2259. Expert Opin Pharmacother. 2008. PMID: 18710351 Review.
295 results